Cell Therapy for Coronary Heart Disease

This study has been terminated.
Information provided by:
Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
First received: February 8, 2006
Last updated: November 29, 2006
Last verified: February 2006

Impaired contractile function after a heart attack and due to coronary heart disease is a major cause of "heart failure" limiting quality of life and prognosis, which cannot be prevented even with optimal standard therapy.

The aim of the current trial is to investigate whether infusion of progenitor cells into the coronary artery supplying the most dyskinetic left ventricular area may improve left ventricular contractile function, compared to no cell infusion in the control group, in patients with old (>= 3 months) myocardial infarction.

Condition Intervention Phase
Coronary Artery Disease
Drug: intracoronary infusion of progenitor cells
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Cell Therapy for Coronary Heart Disease: Infusion of Autologous Ex Vivo Cultivated Endothelial Progenitor Cells (EPCs)” and Autologous Bone Marrow Progenitor Cells in Crossover Design for Improvement of Vascularization and Cardiac Function

Resource links provided by NLM:

Further study details as provided by Johann Wolfgang Goethe University Hospitals:

Primary Outcome Measures:
  • Change in global left ventricular function (measured by quantitative left ventricular angiography)

Secondary Outcome Measures:
  • Quantitative parameters of regional left ventricular function of the target area
  • changes in left ventricular volumes
  • functional status as assessed by NYHA classification
  • event-free survival after 4 months follow-up

Estimated Enrollment: 75
Study Start Date: January 2002
Estimated Study Completion Date: January 2005
Detailed Description:
  • The study is an open-label, controlled, randomized single-center trial.
  • Patients post myocardial infarction (>= 3 months) with a patent infarct-related artery are included.
  • Bone marrow-derived progenitor cells are aspirated under local anaesthesia, and after cell processing, are infused into the patent infarct-related artery during stop flow within the same day. Blood-derived progenitor cells are isolated out of 250ml peripheral venous blood, and after cell processing and 3 days culture, are infused into the patent infarct-related artery during stop flow. In addition, left ventricular angiography is performed. In the control group coronary angiography and left ventricular angiography without any intracoronary infusion are performed.
  • After 3 months, left ventricular angiography is repeated, and patients of the control group cross-over to active treatment with progenitor cells, whereas patients initially treated with progenitor cells cross-over to the alternate cell type.
  • The primary endpoint is the change in quantitative global left ventricular ejection fraction in LV angiography between the groups.

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients aged 18 to 80
  • Patients post-myocardial infarction (> 3 months old) or with diffuse ischemic CHD
  • Signed informed consent

Exclusion Criteria:

- Existing neoplastic disease or signs of tumor recurrence within the last 5 years

  • Active infection
  • Active internal bleeding
  • Stroke within the past 2 years
  • Surgery or trauma within the past two months
  • Uncontrolled hypertension over 160/100
  • Arteriovenous malformations or aneurysms
  • HIV infection
  • Signs of significant kidney or liver failure (creatinine > 2.0 mg/dL, GOT > 2 x upper standard value)
  • Thrombopenia (< 100,000)
  • Anemia (hemoglobin < 8.5 g/dL)
  • Mental retardation
  • Participation in another clinical study
  • Women of childbearing age
  • Chronic inflammatory disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00289822

J. W. Goethe University Hospitals
Frankfurt, Germany, 60590
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospitals
Principal Investigator: Andreas M Zeiher, MD J. W. Goethe University Hospitals
Study Director: Volker Schaechinger, MD J. W. Goethe University Hospitals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00289822     History of Changes
Other Study ID Numbers: 158/02 
Study First Received: February 8, 2006
Last Updated: November 29, 2006
Health Authority: Germany: Paul-Ehrlich-Institut

Keywords provided by Johann Wolfgang Goethe University Hospitals:
chronic heart failure
myocardial infarction

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Heart Diseases
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on April 27, 2016